



24 August 2010

Company Announcement

PHOSPHAGENICS APPOINTS THREE NEW NON-EXECUTIVE DIRECTORS TO BOOST ITS COMMERCIAL TRANSFORMATION

Stuart James – former CEO & Managing Director of Mayne Pharma

Sandra Webb – Director of Ground Zero Pharmaceuticals

Don Clarke – Partner Minter Ellison, Deputy Chair of Webjet & Director Circadian Technologies

Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) has appointed Mr Stuart James, Dr Sandra Webb and Mr Don Clarke as Non-Executive Directors to formulate and facilitate the implementation of strategies to commercialise the company's research and development pipeline.

All new Directors have senior commercial experience and align with Phosphagenics' transition from product development to product distribution and sales.

Two existing directors, Professor John Mills and Mr Michael Ashton, have resigned from the Board. The company is very grateful to Professor Mills and Mr Ashton for their considerable input and energy.

New Non-Executive Director, Mr Stuart James, has had an outstanding career at Mayne Pharma. Starting out as Chief Operating Officer, he oversaw the restructuring of Mayne's under-performing logistics and hospitals businesses as well as the development of its diagnostic services. He was promoted to Group Managing Director and CEO. With Mr James at the helm, Mayne transformed from a disparate collection of unrelated businesses into two clearly defined entities (domestic healthcare and global injectable generic pharmaceuticals) which formed the basis of the proposed demerger of Mayne Group.

He is currently the Chairman of Pulse Health Limited, Prime Financial Group Limited and Progen Limited. He also serves as Non-Executive Director on the Greencross Limited Board.

Dr Sandra Webb rejoins Phosphagenics, having served with the company as pharmaceutical development advisor from February 2005 to June 2006. Dr Webb is a Director of Ground Zero Pharmaceuticals Pty Limited. She previously served on the Boards of AusBiotech Limited, Amrad Corporation Limited and Quintiles Limited.

An experienced pharmaceutical professional, Dr Webb has a strong track record of achievements in the commercial world of drug development. As Managing Director of Quintiles Australia, she successfully grew the company as the leading commercial research organisation in Australia. Under her stewardship, Quintiles Australia was the most profitable subsidiary of the worldwide Quintiles Transnational Inc.

Dr Webb's research has been published in over 30 prestigious peer reviewed journals including the *Journal of Physiology*, the *British Journal of Pharmacology* and *Nature*.

Since 1988 Mr Don Clarke has been a partner of law firm Minter Ellison. He serves in the Melbourne Private Equity & Capital Markets group, predominantly advising ASX listed companies across a range of industries with emphasis on technology and manufacturing.

Mr Clarke is also the Deputy Chairman of Webjet Limited and a Director of Circadian Technologies Limited.

"As Phosphagenics is building its product pipeline and commercial focus it is also strengthening its board. We welcome our three new Directors who are all commercially savvy and heavy-weights in their respective fields. Phosphagenics is proud to have them on board and I personally look forward to working with them," stated Dr Esra Ogru, CEO of Phosphagenics.

The three new directors join existing directors: Mr Jonathan Addison, Chairman and Non-Executive Director; Mr Harry Rosen, Executive Director; and Dr Esra Ogru, Executive Director.

-ENDS-

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and its ADR – Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.

For more information, please visit Phosphagenics' web site at www.phosphagenics.com

Company Contact (Australia):

Dr Esra Ogru, Chief Executive Officer, Phosphagenics Ltd
Phone: +61 3 9565 1119

Company Contact (United States):

Fred Banti, President, Phosphagenics
Phone: +1 646 706 2155, Email: fbanti@phosphagenics.com

Rudi Michelson

Monsoon Communications
Phone: +61 3 9620 3333